Diabetic Retinopathy

ICYMI: Dr. Singh shares the take-home message from his 2019 presentation

ICMYI: Dr. Wykoff discusses results from his ASRS presentation

New research confirms agreement with 7 standard field imaging

FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Micoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.

The prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.

Patients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population.

Ultra-widefield imaging has become an important component of a thorough eye exam and is taking on a larger role in retina and comprehensive ophthalmology.

Study results provide new information about the risk and strategies for preventing tractional retinal detachment (TRD) development or progression in eyes with severe proliferative diabetic retinopathy (PDR) receiving intravitreal bevacizumab (Avastin, Genentech) prior to vitrectomy.

In complicated retinal detachment cases where the retina fails to reattach after completing the usual steps, retinectomy is a better technique than relaxing retinotomy–and the retinectomy is best done incrementally under air, said Steve Charles, MD.

Anti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.

Intravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.

New imaging technologies, such as ultra-wide-field fluorescein angiography and optical coherence tomography angiography, are providing more details about retinal diseases than previous imaging technologies, leading to better understanding of disease processes.